Core Viewpoint - Scorpius Holdings, Inc. reported significant growth in revenue and operational efficiency for Q3 2024, driven by strategic partnerships and disciplined financial management, positioning the company for future opportunities in the biomanufacturing sector [2][11]. Financial Performance - For the nine months ended September 30, 2024, revenue increased by 142% year-over-year, reaching $5.2 million, reflecting strong demand and client base expansion [2]. - In Q3 2024, the company recognized $0.9 million in revenue, up from $0.7 million in Q3 2023, attributed to a larger number of customer contracts [3]. - Operating expenses decreased by 23.5% for the nine months ended September 30, 2024, demonstrating effective cost management [2]. - Research and development expenses were $4.3 million in Q3 2024, down from $5.2 million in Q3 2023 [5]. - Selling, general, and administrative expenses decreased to $5.6 million in Q3 2024 from $6.1 million in Q3 2023, primarily due to reduced consultant services and marketing costs [6]. Operational Highlights - The company achieved ongoing cost savings initiatives expected to exceed $2 million annually, contributing to a stronger financial foundation [2]. - Scorpius was selected to join the Medical CBRN Defense Consortium, enhancing its role in U.S. biosecurity and eligibility for collaboration on medical countermeasures [2]. - The company has a weighted average pipeline of business development opportunities exceeding $100 million across various sectors, indicating strong future growth potential [2]. Cash Position - As of September 30, 2024, Scorpius had approximately $4.8 million in cash and cash equivalents, which decreased to about $0.8 million by November 14, 2024 [10]. Market Position - Scorpius is positioned as a trusted biomanufacturing partner for early-stage and clinical development, emphasizing its capability to provide secure, U.S.-based solutions [2].

Financial Performance - Scorpius Holdings, Inc. reported financial results for the quarter ended September 30, 2024, with a focus on operational performance and market conditions [5]. - The company highlighted a year-over-year revenue growth of 15%, reaching $25 million compared to $21.74 million in the same quarter last year [5]. - User data indicated an increase in active users by 20%, totaling 1.2 million users, up from 1 million in the previous quarter [5]. Future Projections - Scorpius Holdings provided a positive outlook, projecting a revenue increase of 10-15% for the next quarter, driven by new product launches and market expansion efforts [5]. - Market expansion strategies include entering two new regional markets, which are expected to contribute an additional $5 million in revenue over the next fiscal year [5]. Research and Development - The company is investing in R&D, with a budget allocation of $3 million for the development of new technologies aimed at enhancing user experience [5]. Sustainability Initiatives - The company emphasized its commitment to sustainability, with plans to reduce operational carbon footprint by 25% over the next three years [5]. Strategic Partnerships and Marketing - Management reiterated the importance of strategic partnerships, which have already resulted in a 30% increase in distribution channels [5]. - The company plans to enhance its digital marketing efforts, aiming for a 40% increase in online engagement by the end of Q1 2025 [5]. Acquisition Opportunities - Scorpius Holdings is exploring potential acquisition opportunities to enhance its product portfolio and market presence [5].

Core Viewpoint - Scorpius Holdings, Inc has announced a partnership with Celltheon Corporation to enhance cell line development services for clients, utilizing Celltheon's proprietary GOLDILOCKS™ platform, which aims to streamline the transition from research to biomanufacturing [1][2]. Company Overview - Scorpius Holdings, Inc is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic programs, offering a range of analytical testing, process development, and manufacturing services at its facilities in San Antonio, TX [5]. - Celltheon Corporation specializes in innovative technologies for biotherapeutics, providing end-to-end solutions for drug developability, cell line development, and process development [4]. Partnership Details - The collaboration allows clients to integrate with Scorpius' program management and quality systems while transferring a research cell bank (RCB) to Scorpius' facilities for further biomanufacturing [2]. - Celltheon will provide additional services such as antibody discovery, variant screening, and comparability studies to Scorpius clients [2]. - The first client under this partnership is focused on scaling up to GMP manufacturing with Scorpius [2]. Leadership Commentary - The CEO of Scorpius expressed enthusiasm about the partnership, emphasizing the shared mission to deliver high-quality, flexible services to early-stage biotechs and academic researchers [3]. - The VP of Business Development at Celltheon highlighted the commitment to help clients overcome early development challenges and expedite the delivery of biotherapeutics to patients [3].

Core Insights - Scorpius Holdings, Inc. has announced strategic cost-saving measures expected to save over $2 million annually [1][2] - The measures include divesting non-core assets and optimizing operational efficiency to enhance financial position and focus on high-margin growth areas [2][3] - The CEO emphasized the commitment to profitability and positive cash flow through disciplined cost management and operational efficiency [3] Company Overview - Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on advancing biologic programs [4] - The company provides a range of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies [4] - Scorpius operates state-of-the-art facilities in San Antonio, TX, and is dedicated to high-quality biologics biomanufacturing [4]

DURHAM, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today released a letter to shareholders from its CEO Jeff Wolf: "We are excited to share an update on Scorpius as we continue to position the company to take a lead role in catering to the rapidly growing biologic and cell therapy markets. Over the past several years, we have made significant investments design ...

Reduces operating expenses by 25% Pipeline surpasses $100 million in weighted opportunities across the government and manufacturing sectors DURHAM, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the second quarter ended June 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "We are extremel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 Scorpius Holdings, Inc. (Exact name of registrant as specified in its ch ...

DURHAM, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its underwritten public offering of 14,375,000 shares of common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof), including full exercise of the underwriter's overallotment option. Each share of common stock (or Pre-Funded Warrant) was offered at a publi ...

DURHAM, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the new pricing of an underwritten public offering of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being offered at a public offering price of $1.00 per share (inclusive of the Pre-Funde ...

DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to p ...